4:58 PM
 | 
Mar 20, 2014
 |  BC Extra  |  Company News

Breakthrough designation for Pfizer's meningococcal B vaccine

Pfizer Inc. (NYSE:PFE) said FDA granted breakthrough therapy designation for bivalent rLP2086 to prevent meningococcal B...

Read the full 69 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >